APA

Smith D. C., Tangen C. M., Van Veldhuizen P. J., Harrer G. W., Golshayan A., Mills G. M., Vogelzang N. J., Thompson I. M. & Hussain M. H. A. (20110719). Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. : Urology.

Chicago

Smith David C, Tangen Cathy M, Van Veldhuizen Peter J, Harrer Grant W, Golshayan Ali, Mills Glenn M, Vogelzang Nicholas J, Thompson Ian M and Hussain Maha H A. 20110719. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. : Urology.

Harvard

Smith D. C., Tangen C. M., Van Veldhuizen P. J., Harrer G. W., Golshayan A., Mills G. M., Vogelzang N. J., Thompson I. M. and Hussain M. H. A. (20110719). Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. : Urology.

MLA

Smith David C, Tangen Cathy M, Van Veldhuizen Peter J, Harrer Grant W, Golshayan Ali, Mills Glenn M, Vogelzang Nicholas J, Thompson Ian M and Hussain Maha H A. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. : Urology. 20110719.